Drotrecogin alpha: a rational approach to the treatment of submassive pulmonary embolism?

作者：Samama Charles Marc^*; Godier Anne

来源：Critical Care, 2011, 15(1): 123.

DOI：10.1186/cc10027

Combining therapeutic doses of low-molecular-weight heparins and increasing doses of recombinant activated protein C - Drotrecogin alpha (activated), or DAA - is of theoretical interest with regard to the control of coagulation activation. The study by Dempfle and colleagues presents new data showing that endogenous activated protein C levels do not increase in nonseptic patients with pulmonary embolism. However, the results of the addition of these two treatments are puzzling, leaving unresolved the questionable clinical relevance of this combination and the possible increase in bleeding risk.

• 出版日期2011